Condition: Multiple Sclerosis (MS)
Interventions: Drug: Ocrelizumab; Drug: rHuPH20
Sponsor: Hoffmann-La Roche
Not yet recruiting
ClinicalTrials.gov: Neurology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis
June 3, 2019ClinicalTrials.govComments OffNeurologyAdministration | Investigate | Multiple | Ocrelizumab | Patients | Pharmacokinetics | Safety | Sclerosis | Study | Subcutaneous | Tolerability
Comments
